What does CUSIP 22663K107 represent in this 13F holders report?

CUSIP 22663K107 is the security identifier for CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock in Q2 2022?

109 institutional investors reported CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock for Q2 2022. Use the holders table for investor-level position and value details.

Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

CUSIP: 22663K107

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class: Equity / Common Stock
Shares outstanding: 94,401,153
Total 13F shares: 50,645,843
Share change: +5,242,742
Total reported value: $944,532,132
Price per share: $18.65
Number of holders: 109
Value change: +$94,595,270
Number of buys: 59
Number of sells: 47

Quarterly Holders Quick Answers

What is CUSIP 22663K107?
CUSIP 22663K107 identifies CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2022
Previous quarter: Q1 2022

Recent filing periods for CUSIP 22663K107:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PERCEPTIVE ADVISORS LLC	3/4/5 13F	10%+ Owner · Company	5.5% from 13F	5,321,032	$200,336,855	—	18 Apr 2022	3/4/5 13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	5.2%	4,944,013	$108,521,000	—	31 Mar 2022	13F
FMR LLC	13F	Company	3.5%	3,337,395	$73,256,000	—	31 Mar 2022	13F
BlackRock Finance, Inc.	13F	Company	3.5%	3,296,780	$72,365,000	—	31 Mar 2022	13F
ORBIMED ADVISORS LLC	13F	Company	3.4%	3,196,876	$70,171,000	—	31 Mar 2022	13F
BVF INC/IL	13F	Company	3.2%	3,003,879	$65,935,000	—	31 Mar 2022	13F
VANGUARD GROUP INC	13F	Company	2.2%	2,099,313	$46,079,000	—	31 Mar 2022	13F
Bain Capital Life Sciences Investors, LLC	13F	Company	2.2%	2,029,701	$44,552,000	—	31 Mar 2022	13F
STATE STREET CORP	13F	Company	1.8%	1,700,679	$37,330,000	—	31 Mar 2022	13F
Deep Track Capital, LP	13F	Company	1.6%	1,541,715	$33,841,000	—	31 Mar 2022	13F
Frazier Life Sciences Management, L.P.	13F	Company	1.5%	1,414,823	$31,055,000	—	31 Mar 2022	13F
Point72 Asset Management, L.P.	13F	Company	1.3%	1,206,338	$26,479,000	—	31 Mar 2022	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	1.1%	1,029,364	$22,595,000	—	31 Mar 2022	13F
5AM Venture Management, LLC	13F	Company	0.91%	862,286	$18,927,000	—	31 Mar 2022	13F
BAKER BROS. ADVISORS LP	13F	Company	0.88%	827,480	$18,163,000	—	31 Mar 2022	13F
EcoR1 Capital, LLC	13F	Company	0.84%	790,209	$17,345,000	—	31 Mar 2022	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.78%	740,385	$16,251,000	—	31 Mar 2022	13F
Opaleye Management Inc.	13F	Company	0.73%	693,000	$15,211,000	—	31 Mar 2022	13F
First Light Asset Management, LLC	13F	Company	0.62%	582,767	$12,792,000	—	31 Mar 2022	13F
SPHERA FUNDS MANAGEMENT LTD.	13F	Company	0.55%	521,947	$11,457,000	—	31 Mar 2022	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.52%	489,357	$10,736,000	—	31 Mar 2022	13F
NORTHERN TRUST CORP	13F	Company	0.47%	440,524	$9,669,000	—	31 Mar 2022	13F
Novo Holdings A/S	13F	Company	0.45%	424,897	$9,326,000	—	31 Mar 2022	13F
Versant Venture Management, LLC	13F	Company	0.43%	410,360	$9,007,000	—	31 Mar 2022	13F
MPM BioImpact LLC	13F	Company	0.39%	366,676	$8,049,000	—	31 Mar 2022	13F
Ajay Madan	3/4/5	Chief Development Officer	— mixed-class rows	242,395 mixed-class rows	$7,783,510	—	28 Feb 2022	3/4/5
Bank of New York Mellon Corp	13F	Company	0.34%	317,037	$6,958,000	—	31 Mar 2022	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.32%	298,125	$6,544,000	—	31 Mar 2022	13F
Nuveen Asset Management, LLC	13F	Company	0.31%	297,125	$5,646,000	—	31 Mar 2022	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.25%	236,160	$5,184,000	—	31 Mar 2022	13F
Altium Capital Management LLC	13F	Company	0.22%	204,000	$4,478,000	—	31 Mar 2022	13F
Walleye Capital LLC	13F	Company	0.19%	183,543	$4,029,000	—	31 Mar 2022	13F
FIRST MANHATTAN CO. LLC.	13F	Company	0.16%	152,200	$3,340,000	—	31 Mar 2022	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.15%	141,300	$3,102,000	—	31 Mar 2022	13F
New Leaf Venture Partners, L.L.C.	13F	Company	0.15%	141,000	$3,095,000	—	31 Mar 2022	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.13%	120,777	$2,651,000	—	31 Mar 2022	13F
SILVERARC CAPITAL MANAGEMENT, LLC	13F	Company	0.12%	114,004	$2,502,000	—	31 Mar 2022	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.12%	110,603	$2,428,000	—	31 Mar 2022	13F
VICTORY CAPITAL MANAGEMENT INC	13F	Company	0.12%	110,278	$2,421,000	—	31 Mar 2022	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.1%	97,933	$2,150,000	—	31 Mar 2022	13F
MORGAN STANLEY	13F	Company	0.1%	95,290	$2,092,000	—	31 Mar 2022	13F
Ghost Tree Capital, LLC	13F	Company	0.09%	85,000	$1,866,000	—	31 Mar 2022	13F
JPMORGAN CHASE & CO	13F	Company	0.09%	81,736	$1,793,000	—	31 Mar 2022	13F
Laurion Capital Management LP	13F	Company	0.08%	79,952	$1,755,000	—	31 Mar 2022	13F
Swiss National Bank	13F	Company	0.08%	78,700	$1,727,000	—	31 Mar 2022	13F
Rafferty Asset Management, LLC	13F	Company	0.08%	78,135	$1,715,000	—	31 Mar 2022	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.08%	77,907	$1,710,000	—	31 Mar 2022	13F
UBS Group AG	13F	Company	0.07%	68,493	$1,504,000	—	31 Mar 2022	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.06%	61,300	$1,346,000	—	31 Mar 2022	13F
Ensign Peak Advisors, Inc	13F	Company	0.06%	60,961	$1,338,000	—	31 Mar 2022	13F

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) as of Q2 2022

As of 30 Jun 2022, Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX) was held by 109 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 50,645,843 shares. The largest 10 holders included DRIEHAUS CAPITAL MANAGEMENT LLC, PERCEPTIVE ADVISORS LLC, BlackRock Inc., BVF INC/IL, ORBIMED ADVISORS LLC, FMR LLC, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, WELLINGTON MANAGEMENT GROUP LLP, and STATE STREET CORP. This page lists 109 institutional shareholders reporting positions in this security for the Q2 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders

114

Q2 2022 holders

109

Holder diff

-5

Investor	Q1 2022 Shares	Q2 2022 Shares	Share Diff	Share Chg %	Q1 2022 Value $	Q2 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.